Screening Malaria-box compounds to identify potential inhibitors against SARS-CoV-2 MPro, using molecular docking and dynamics simulation studies

Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) Main protease (M-pro) is one of the vital drug targets amongst all the coronaviruses, as the protein is indispensable for virus replication. The study aimed to identify promising lead molecules against M-pro enzyme through virtual screening of Malaria Venture (MMV) Malaria Box (MB) comprising of 400 experimentally proven compounds. The binding affinities were studied using virtual screening based molecular docking, which revealed five molecules having the highest affinity scores compared to the reference molecules. Utilizing the established 3D structure of M-pro the binding affinity conformations of the docked complexes were studied by Molecular Dynamics (MD) simulations. The MD simulation trajectories were analysed to monitor protein deviation, relative fluctuation, atomic gyration, compactness covariance, residue-residue map and free energy landscapes. Based on the present study outcome, we propose three Malaria_box (MB) compounds, namely, MB_241, MB_250 and MB_266 to be the best lead compounds against M-pro activity. The compounds may be evaluated for their inhibitory activities using experimental techniques.

Automated summary

The study identified three promising lead compounds from the MMV Malaria Box through virtual screening against M-pro enzyme. These compounds may be evaluated for their inhibitory activities using experimental techniques.